NeoKen Bio establishing KRW 15 billion CBD finished‑pharmaceutical manufacturing facility — aiming to be operational by 2027

NeoKen Bio is building a CBD finished‑pharmaceutical manufacturing facility valued at KRW 15 billion. Targeted to be operational in 2027, the project’s core objective is to create an end‑to‑end supply chain—from regional hemp cultivation through ingredient extraction to finished drug production. The facility is being positioned as key infrastructure for domestic self‑sufficiency in CBD pharmaceuticals.

For the full article, please visit the original source link below. CannabisInsight curates and summarizes key news from the global cannabis and hemp industry.